Periodic veganism in healthy individuals improves blood lipids, reduces low-grade inflammation, but impairs bone health: the FastBio study

Eleni M. Loizidou[1,2], Petros Barbounakis[3], Stavros Glentis[1,4], Alexandros Dimopoulos[1,5], Maria Anezaki[1], Pavlos Rouskas[6], Ioannis Kontoyiannis[7], Nikolaos Demiris[3], Konstantinos Rouskas[1,8], Antigone S. Dimas[1*]

[1] Institute for Bioinnovation, Biomedical Sciences Research Center 'Alexander Fleming', Fleming 34, 16672, Vari, Greece

[2] biobank.cy Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Cyprus

3 Department of Statistics, Athens University of Economics and Business, Athens, Greece

[4] Pediatric Hematology/Oncology Unit (POHemU), First Department of Pediatrics, University of Athens, Aghia Sophia Children's Hospital, Levadias 8, 11527, Athens, Greece

[5] Hellenic Naval Academy, Hatzikyriakou Avenue, Pireaus 185 39, Greece

[6] 1st Department of Cardiology, AHEPA University Hospital, Aristotle University, Thessaloniki, Greece

[7] Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, United Kingdom

[8] Institute of Applied Biosciences, Centre for Research & Technology Hellas, Thessaloniki, Greece

Corresponding author: dimas@fleming.gr

ABSTRACT

Background: Dietary restriction (DR) is gaining ground as a means to prevent and treat a range of conditions and diseases, but possible negative effects on health remain unclear. In our study we address the impact of DR, in the form of periodic abstinence from animal products (periodic veganism), on markers of health.

Methods: We profiled a unique group of 200 periodic vegan (PV) individuals who alternate between an omnivorous and a vegan diet for religious reasons. PV individuals practice veganism for a total of 180-200 days annually, in a temporally structured and highly consistent manner, and have adhered to this diet for at least ten years. We also profiled 211 non-vegan (NV), omnivorous individuals. Traits were measured at two timepoints, the first capturing a period of omnivory for both groups, the second capturing a period during which PV individuals only had followed a vegan diet for three to four weeks. We report results on blood lipids (total, LDL, and HDL cholesterol, triglycerides), glucose metabolism (glucose, insulin, HBA1c), renal function (urea, uric acid, creatinine), liver function (AST, ALT, γ-GT), bone/liver function (ALP), thyroid function (TSH), inflammation (CRP), complete blood counts, anthropometric traits and blood pressure. We used linear mixed effects models to report changes in measured traits across timepoints for each dietary group, and differences of measured traits between dietary groups at each timepoint.

Results: Following three to four weeks of veganism, PV individuals display reduced levels of total and LDL cholesterol [both β=-0.3, 95% CI:(-0.4, -0.2) mmol/L] and of CRP [β=-1.3, 95% CI:(-2.1, -0.5) mg/L] which decreases by 28%. Compared to NV, PV individuals display consistently lower counts of total white blood cells (WBC) [β=-0.4, 95% C.I:(-0.6,-0.3) K/μL] and neutrophils [β=-0.4, 95% C.I:(-0.5,-0.2) $x10^3$/μl], but higher levels of ALP [β=5.9, 95% C.I:(2.7,9.1) U/L].

Conclusions: Abstinence from animal products improves cardiovascular health and reduces low-grade inflammation, but periodic veganism has long-term, detrimental effects on bone health. FastBio is the first highly comprehensive study to unveil the impact of long-term, periodic DR on health and can help inform public health policies on how to harness dietary intake to prevent and treat disease.

Keywords: dietary restriction, vegan, metabolic, blood lipids, low-grade inflammation, bone health

BACKGROUND

Dietary restriction (DR), the reduction of particular or total nutrient intake without malnutrition [1], is gaining in popularity as a powerful intervention for the prevention and treatment of a wide range of chronic conditions, such as obesity and cardiometabolic disease [2]. DR encompasses dietary interventions including caloric restriction, intermittent fasting and restriction of specific nutrients [3]. Studies in model organisms have shown that almost all types of DR influence physiological, metabolic and molecular pathways with mostly beneficial effects on health [3, 4]. Veganism, a dietary pattern involving abstinence from all animal products, constitutes a form of DR that is a growing trend worldwide. In January 2023, 3% and 4 % of the total population in Great Britain (https://yougov.co.uk/) and the USA (https://www.statista.com/) respectively identified as vegan. Vegan diets are characterised by low intake of saturated fats, high intake of dietary fibre, and low intake of micronutrients including vitamin B12, vitamin D, calcium, and iodine [5]. To date, findings from prospective cohorts have linked vegan diets to lower risk of all-cause mortality [6], cancer incidence, diabetes, diverticular disease, cataracts [5-7], but to a higher risk of bone fractures [5, 6, 8, 9]. Collectively, cross-sectional and interventional studies associate plant-based diets to beneficial effects on BMI, total and LDL cholesterol, blood glucose, CRP, serum urea, urinary creatinine and γ-GT [10-16]. Although relatively few studies have systematically investigated the impact of a vegan diet on inflammatory biomarkers [17,

18], evidence suggests an impact on immune system function, with one of the most prominent effects being improved inflammatory activity in rheumatoid arthritis patients [19]. However, most studies are not comprehensive and report on a limited number of outcomes or measurements. Furthermore, studies involving large numbers of individuals are cross-sectional and while they build on existing knowledge, they do not allow for causal inference. Important insight has been provided by meta-analyses of observational studies and randomised controlled trials (RCTs), but these studies suffer from limitations arising from the heterogeneity of primary studies analysed. Heterogeneity may pertain to the duration of the dietary intervention (a few weeks to several months), to the health status of participants (e.g. healthy, obese, at-risk, patients), to the dietary intake of control groups (e.g. no dietary intervention, specific dietary interventions), and to lack of adjustment for important confounders (e.g. sex, age, and BMI). Furthermore, in the past, many studies combined vegan and vegetarian individuals in a single study group, thus obscuring vegan-specific effects given that exclusively plant-based diets are substantially more restricted than vegetarian regimens [13, 14].

To address the gaps in our knowledge, we established FastBio (Religious Fasting Biology), a highly comprehensive study exploring the effects of periodic abstinence from animal products on markers of health. FastBio focuses on a unique group of individuals who alternate between omnivory and veganism for religious reasons, in a temporally structured and highly consistent manner. We explore effects of this dietary behaviour on markers of health and compare findings to a continuously omnivorous group from the general population.

METHODS

Study population

Following screening of over 1,000 candidate participants from the greater area of Thessaloniki, Greece, we selected 411 apparently healthy, unrelated individuals who met FastBio selection criteria (Additional File 1: Supplementary Text S1). Participants belonged to one of two groups,

specified by type of diet: 200 periodic vegan (PV) and 211 non-vegan (NV) individuals. PV individuals alternate between an omnivorous and a vegan type of diet, abstaining from meat, fish, dairy products and eggs for 180-200 days annually. They do not abstain from molluscs and shellfish. Abstinence is practiced for religious reasons, in accordance to the dietary regimen specified by the Christian Orthodox Church and is typically initiated in childhood. PV individuals constitute a unique study group, in that the type of DR practised is highly consistent across practising individuals and is temporally structured with a specific periodicity throughout the year that involves four extended periods of abstinence, as well as abstinence on Wednesdays and Fridays of each week (Additional File 1: Supplementary Fig. S1). During periods of abstinence, PV individuals also typically consume less alcohol. When not abstaining, PV individuals follow an omnivorous type of diet. Only PV individuals who had practised this type of DR for at least ten years were included in the FastBio study. NV participants were omnivorous individuals from the general population, who were not under any kind of DR or special diet.

Collection of data, of biological material and measurement of traits

FastBio participants were invited to two scheduled appointments at the Interbalkan Hospital of Thessaloniki. The first appointment took place in autumn [Timepoint 1 (T1)] and covered a period where all PV individuals had been on an omnivorous diet (excluding Wednesdays and Fridays) for eight or nine weeks. The second appointment [Timepoint 2 (T2)] took place in spring and covered a period during which PV individuals had abstained for at least three and a maximum of four weeks. Prior to this period of abstinence, all PV individuals had been on an omnivorous type of diet for seven to eight weeks. At T2, a recall rate of 95% was achieved, with 192 (out of 200) PV participants and 198 (out of 211) NV participants attending both appointments. All appointments were scheduled between 7:30-9:30 am to minimize circadian effects and were completed during a two-week window to minimize effects of seasonality [15]. The ethics committee of BSRC Alexander Fleming approved the study protocols, the study was

performed in line with the principles of the Declaration of Helsinki, and all participants provided written informed consent.

For each participant, following overnight fasting, a blood sample was collected by a certified nurse and was taken for biomarker and complete blood count (CBC) testing at the InterBalkan Hospital facilities. We report results on 16 blood (serum) biomarker traits and 23 CBC traits (Additional File 1: Supplementary Table S1). Biomarkers were grouped to allow for broad interpretation [10]: blood lipids (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides), glucose metabolism (glucose, insulin, HBA1c), renal function (urea, uric acid, creatinine), liver function (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (γ-GT)), bone and liver function (alkaline phosphatase (ALP)), thyroid function (thyroid-stimulating hormone (TSH)), and inflammation (C-reactive protein (CRP)). Using glucose and insulin measurements, we calculated homeostatic model assessment (HOMA) indices to assess beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) (Additional File 1: Supplementary Text S2). Height was measured to the nearest 0.5 cm using a stadiometer. Body weight was measured with the use of a calibrated digital scale with an accuracy of ±100g. BMI was calculated as body weight divided by the square of height (kg/m^2). Systolic and diastolic blood pressure (SBP and DBP respectively) were measured using a traditional sphygmomanometer. Information on lifestyle, dietary intake and family history was also collected.

Statistical analysis

We conducted multivariable regression analysis by fitting linear mixed effects (lme) models with random effects ("nlme" R version 4.1.1) for each measured trait. The sampling distribution for each trait was investigated and eight non-normally distributed traits (triglycerides, glucose, insulin, creatinine, AST, ALT, γ-GT and CRP) were log-transformed prior to regression analyses. We report: A) changes in measured traits across timepoints for each dietary group, and B) differences of measured traits between the two dietary groups for each given timepoint

(Additional File 1: Supplementary Fig. S2). For (A) eight PV and 13 NV individuals were excluded because they were not present at T2 and findings are from 192 PV and 198 NV individuals with paired data, meaning that each individual acts as his/her own control. For (B) we report results from 200 PV and 211 NV individuals at T1, and from 192 PV and 198 NV individuals at T2. Results are presented as betas and 95% CI. *P* values < 0.05 were considered statistically significant. Changes for each dietary group across timepoints are reported with reference to T2. Differences between dietary groups for each timepoint are reported with reference to the PV group.

Blood biomarkers and CBC traits

We fitted lme models on measured traits with sex, age, and BMI as fixed confounders (Additional File 1: Supplementary Text S3, Supplementary Table S2) and included an interaction term between dietary group (PV or NV) and timepoint (T1 or T2) to conduct comparisons. We also corrected for medication use to account for effects on measured traits (Additional File 1: Supplementary Text S4). Adjusting for smoking and alcohol consumption did not have an impact on our results (Additional File 1: Supplementary Text S4). Individual heterogeneity was accounted for by including participant ID as a random intercept. As a sensitivity analysis for blood biomarkers and CBC traits, we fitted a multivariate regression model using the “lm” function in R. Similarly to lme, individuals with missing data were excluded from the model while the adjustments were the same as in the multivariable analysis.

Anthropometric traits and blood pressure

We fitted lme models on weight and BMI as described above, but without adjustment for BMI. We also fitted lme models for SBP and DBP with the above covariates, adjusting additionally for smoking status, which is a known risk factor for hypertension [16]. Participants were defined as smokers and non-smokers (with past smokers and e-cigarette users also considered as non-

smokers) based on NHS guidelines (https://www.nhs.uk/live-well/quit-smoking/using-e-cigarettes-to-stop-smoking/).

RESULTS

Characteristics of FastBio Participants

Characteristics of FastBio participants are summarised in Table 1 and Additional File 1: Supplementary Table S2. PV individuals (51.5 years) were on average older than NV (45.0 years). Both groups consisted of slightly more female participants (54.0% in PV and 55.0% in NV groups). On average, both groups were overweight, with a higher BMI being recorded for the PV (28.4 kg/m^2) compared to the NV group (26.2 kg/m^2). Most participants were non-smokers (never smoked or stopped) although we report a significant difference across dietary groups (93.5% in PV and 66.9% NV groups, p = 3.8e-11). The vast majority self-reported as healthy, although a minority had underlying chronic conditions, including diabetes, arterial hypertension and hypothyroidism, for which treatment was being received (Additional File 1: Supplementary Table S3). Very few participants were receiving dietary supplements (Additional File 1: Supplementary Text S5). Mean values of blood biomarkers and CBC traits are summarised in Additional File 1: Supplementary Table S1.

Table 1. Participant characteristics at timepoint 1 (T1)

	PV (N=200)	**NV (N=211)**	**Total (N=411)**	***P*-value (PV vs NV)**
Age (mean years ± SD)	51.5 ± 13.5	45.0 ± 13.1	48.1±13.6	1.3e-6
Sex (female/male)	108/92	116/95	224/187	0.9
BMI (mean kg/m^2 ± SD)	28.4 ± 4.6	26.2 ± 4.4	27.3 ± 4.6	1.3e-6
Smoking status (No/Yes)	187/13	141/70	328/83	3.8e-11
Blood pressure				
SBP	127±19.0	121±19.7	124±19.4	0.003
DBP	80±10.8	78±11.8	79±11.3	0.04

BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure

Changes in measured traits for each dietary group across timepoints

Table 2 and Table 3 summarise the changes in measured traits across timepoints for each dietary group.

Blood biomarkers

Among the 16 blood biomarkers measured, multivariable analysis yielded significant changes from T1 to T2 for 13 biomarkers in the PV group and for four biomarkers in the NV group (Table 2). Of these, we validated seven biomarkers for the PV group and a single biomarker for the NV group through sensitivity analysis (Additional File 1: Supplementary Table S4). Validated findings in PV individuals include a prominent reduction in total cholesterol [-0.3 mmol/L (-0.4 to -0.2)], LDL cholesterol [-0.3 mmol/L (-0.4 to -0.2)] (Fig.1 and Additional File 1: Supplementary Fig. S3), urea [-5.8 mg/dL (-6.9 to -4.8)], creatinine [-0.06 mg/dL (-0.07 to -0.04)], ALT [-0.09 U/L (-0.1 to -0.05)], and γ-GT [-0.1 U/L (-0.2 to -0.1]. Furthermore, we report a 28% decrease in levels of CRP [-1.3 mg/L (-2.1 to -0.5)] after excluding individuals with values suggesting acute inflammation (CRP>5 mg/L) (Additional File 1: Supplementary Table S5). Although not validated through sensitivity analysis, in PV individuals only, we report a significant increase in levels of ALP, a small reduction in levels of HDL cholesterol and HbA1c, and a small increase for triglycerides, insulin and AST (Table 2). Notably, through multivariable analysis we also detected an increase in HOMA-B [13.3 (2.1 to 24.5)] for PV individuals. In NV individuals we validated only a small decrease in levels of γ-GT [-0.09 mg/dL (-0.1, -0.06)]. Although not replicated through sensitivity analysis, we also report a very small increase in levels of glucose and TSH, and a small decrease in creatinine (Table 2).

Fig.1



Prominent shift toward normal LDL cholesterol levels in PV individuals only. At T1, 51.0% and 41.0% of PV and NV individuals respectively were above highest normal values for LDL cholesterol. At T2, 15.6% of high-risk PV individuals shifted into the normal range (p = 6.5e-13). These shifts suggest improved cardiovascular health at T2 for PV individuals. No shifts were observed for the NV group (p = 0.08). Top and bottom panels represent PV and NV groups respectively. The dotted line represents the highest normal value for LDL cholesterol (normal range: < 3.4 mmol/L).

<u>CBC traits</u>

Among the 23 CBC traits measured, multivariable analysis yielded significant changes from T1 to T2 for 16 traits in the PV group and for 12 traits in the NV group (Table 3). For both dietary groups we validated changes in total white blood cells (WBC) (PV [-0.4 K/µL (-0.6 to -0.3)], NV [-0.3 K/µl (-0.5 to -0.2)]), lymphocyte % (PV [1.6% (0.7 to 2.5)], NV [1.6% (0.8 to 2.5)]), monocyte % (PV [0.7% (0.5 to 0.9)], NV [0.6% (0.4 to 0.8)]) neutrophils (PV [-0.4 x10^3/µL (-0.5 to -0.2)], NV [-0.3 (-0.4 to -0.2)]), and neutrophil % (PV [-2.5% (-3.5 to -1.6)], NV [-2.1 (-3.05 to -1.2)]) (Additional File 1: Supplementary Table S6). Although not validated through sensitivity analysis, for both groups we also report an increase in monocytes and a decrease in red blood cell traits (MCH, MCV, RDW CV (validated in the NV group) RDW SD) and P-LCR

(Table 3). Additionally, in the PV group only, we report an increase in eosinophil %, as well as a decrease in levels of hemoglobin, hematocrit, MCHC, and platelets. In the NV group only we report a small increase in red blood cells (RBC) (Table 3).

Anthropometric traits and blood pressure

In PV individuals, no changes in weight or BMI were observed across timepoints (Additional File 1: Supplementary Table S7). In the NV group, we report an increase in weight [1.0 kg (0.5 to 1.5)], but with no effect on BMI. Furthermore, for both dietary groups, a decrease in DBP was observed at T2 (PV [-2.5 mmHg (-3.7 to -1.2)], NV [-2.2 mmHg (-3.5 to -1.0)]), with the NV group also displaying decreased SBP [-2.2 mmHg (-4.2 to -0.2)]. A trend toward the same direction for SBP was observed for the PV group [-1.9 mmHg (-3.9 to 0.09)] (Additional File 1: Supplementary Table S7).

Table 2. Changes in blood biomarkers for PV and NV dietary groups across timepoints.

		PV					NV			
Measured traits	**Units**	**PV Estimate**	***P*-value**	**Lower CI**	**Upper CI**		**NV Estimate**	***P*-value**	**Lower CI**	**Upper CI**
Blood Biomarkers										
Total cholesterol	mmol/L	**-0.3**	**<0.0001*** **	**-0.4**	**-0.2**		0.03	0.4	-0.04	0.1
LDL	mmol/L	**-0.3**	**<0.0001*** **	**-0.4**	**-0.2**		-0.04	0.3	-0.1	0.03
HDL	mmol/L	**-0.07**	**<0.0001*** **	**-0.1**	**-0.04**		-0.01	0.4	-0.04	0.01
Triglycerides	mmol/L	**1.3e-3**	**0.04***	**1.03e-4**	**2.6e-3**		5.2e-4	0.4	-6.5e-4	1.8e-3
Glucose	mmol/L	2e-4	0.5	-4e-4	0.008		**6e-4**	**0.03***	**1e-4**	**0.002**
Insulin	mU/L	**0.07**	**0.03***	**0.01**	**0.1**		0.04	0.2	-0.02	0.1
HbA1c	%	**-0.03**	**0.05***	**-0.06**	**-5e-4**		0.002	0.9	-0.03	0.03
Urea	mg/dL	**-5.8**	**<0.0001*** **	**-6.9**	**-4.8**		0.2	0.7	-0.8	1.2
Uric acid	mg/dL	-0.06	0.20	-0.1	0.03		-0.02	0.6	-0.11	0.06
Creatinine	mg/dL	**-0.06**	**<0.0001*** **	**-0.07**	**-0.04**		**-0.02**	**0.01***	**-0.04**	**-0.004**
AST	U/L	**0.04**	**0.03***	**0.004**	**0.07**		0.02	0.3	-0.02	0.05
ALT	U/L	**-0.09**	**0.0001*** **	**-0.1**	**-0.05**		-0.04	0.06	-0.09	0.002
γ-GT	U/L	**-0.1**	**<0.0001*** **	**-0.2**	**-0.1**		**-0.09**	**<0.0001*** **	**-0.1**	**-0.06**
ALP	U/L	**2.5**	**<0.0001*** **	**1.3**	**3.7**		0.5	0.4	-0.6	1.7
TSH	mIU/L	0.05	0.5	-0.08	0.2		**0.1**	**0.04***	**0.01**	**0.3**
CRP	mg/L	**-1.3**	**0.001** **	**-2.1**	**-0.5**		-0.4	0.3	-1.3	0.4
HOMA										
HOMA-B	--	**13.3**	**0.02***	2.1	24.5		-3.8	0.5	-14.9	7.2
HOMA-IR	--	0.2	0.4	-0.3	0.7		-0.2	0.4	-0.7	0.3
P-value: *** ≤ 0.05, ** ≤ 0.001, *** ≤ 0.0001**										

Comparisons are reported with reference to T2. Positive effect estimates indicate an increase in blood biomarkers at T2, negative effect estimates indicate a decrease.

LDL = Low-Density Lipoprotein, HDL = High-Density Lipoprotein, HbA1c = Hemoglobin A1c, AST = Aspartate Aminotransferase, ALT = Alanine Aminotransferase, γ-GT = Glutamyltransferase, ALP = Alkaline Phosphatase, TSH = Thyroid-Stimulating Hormone, CRP = C-Reactive Protein, HOMA = Homeostasis Model Assessment, HOMA-B =HOMA- Beta-Cell Function , HOMA-IR = HOMA- Insulin Resistance

Table 3. Changes in CBC traits for PV and NV dietary groups across timepoints.

		PV					NV			
Measured traits	**Units**	**PV Estimate**	***P*-value**	**Lower CI**	**Upper CI**		**NV Estimate**	***P*-value**	**Lower CI**	**Upper CI**
WBC	K/µL	**-0.4**	**<0.0001*** **	**-0.6**	**-0.3**		**-0.3**	**0.0001*** **	**-0.5**	**-0.2**
Lymphocytes	x10³/µl	-0.04	0.1	-0.09	0.01		-0.008	0.8	-0.06	0.04
Lymphocyte %	%	**1.6**	**0.0004** **	**0.7**	**2.5**		**1.6**	**0.0003** **	**0.8**	**2.5**
Eosinophils	x10³/µl	0.0006	0.4	-0.008	0.02		-0.01	0.07	-0.03	0.001
Eosinophil %	%	**0.2**	**0.02* **	**0.05**	**0.4**		-0.04	0.7	-0.2	0.2
Monocytes	x10³/µl	**0.02**	**0.02* **	**0.003**	**0.03**		**0.02**	**0.005* **	**0.007**	**0.04**
Monocyte %	%	**0.7**	**<0.0001*** **	**0.5**	**0.9**		**0.6**	**<0.0001*** **	**0.4**	**0.8**
Basophils	x10³/µl	0.0007	0.7	-0.003	0.004		-0.0004	0.8	-0.004	0.003
Basophil %	%	0.01	0.5	-0.02	0.05		-0.01	0.4	-0.05	0.02
Neutrophils	x10³/µl	**-0.4**	**<0.0001*** **	**-0.5**	**-0.2**		**-0.3**	**<0.0001*** **	**-0.4**	**-0.2**
Neutrophil %	%	**-2.5**	**<0.0001*** **	**-3.5**	**-1.6**		**-2.1**	**<0.0001*** **	**-3.05**	**-1.2**
RBC	M/mL	0.004	0.8	-0.02	0.03		**0.07**	**<0.0001*** **	**0.04**	**0.09**
Hemoglobin	g/dL	**-0.2**	**<0.0001*** **	**-0.3**	**-0.1**		-0.02	0.6	-0.1	0.06
Hematocrit	%	**-0.4**	**0.0003** **	**-0.7**	**-0.2**		0.01	0.9	-0.2	0.2
MCH	pg	**-0.5**	**<0.0001*** **	**-0.6**	**-0.4**		**-0.4**	**<0.0001*** **	**-0.5**	**-0.4**
MCHC	g/dL	**-0.2**	**0.0001*** **	**-0.2**	**-0.08**		-0.07	0.08	-0.2	0.008
MCV	fl	**-1.0**	**<0.0001*** **	**-1.2**	**-0.8**		**-1.2**	**<0.0001*** **	**-1.3**	**-1.0**
RDW CV	%	**-0.08**	**0.05* **	**-0.2**	**-4e-5**		**-0.1**	**0.004* **	**-0.2**	**-0.04**
RDW SD	fl	**-0.6**	**<0.0001*** **	**-0.8**	**-0.3**		**-0.8**	**<0.0001*** **	**-1.0**	**-0.5**
Platelets	K/µL	**-9.8**	**<0.0001*** **	**-13.4**	**-6.3**		-3.06	0.09	-6.6	0.4
PDW	%	0.004	1.0	-0.3	0.3		0.02	0.9	-0.2	0.3
MPV	µm	-0.07	0.4	-0.2	0.09		-0.04	0.7	-0.2	0.1
P-LCR	%	**-0.9**	**0.006* **	**-1.6**	**-0.3**		**-1.2**	**0.0003** **	**-1.9**	**-0.6**
P-value: *** ≤ 0.05, ** ≤ 0.001, *** ≤ 0.0001**										

Comparisons are reported with reference to T2. Positive effect estimates indicate an increase in CBC traits at T2, negative effect estimates indicate a decrease.

WBC = White Blood Cells, RBC = Red Blood Cells, MCH = Mean Corpuscular Hemoglobin, MCHC = Mean Corpuscular Hemoglobin Concentration, RDW CV = Red Cell Distribution Width Coefficient Of Variation, Red Cell Distribution Width Standard Deviation = RDW SD, PDW = Platelet Distribution Width, MPV = Mean Platelet Volume, P-LCR = Platelet-Large Cell Ratio

Differences of measured traits between dietary groups for each timepoint

Table 4 and Table 5 summarise the differences of measured traits between dietary groups, for each sampling timepoint.

Blood biomarkers

At T1, when both dietary groups were following an omnivorous diet, PV and NV individuals share a very similar blood biomarker profile. We only report differences in two out of 16 biomarkers, namely higher levels in the PV group of ALP [3.6 U/L (0.2 to 6.9)], and of TSH [0.3 mIU/L (0.03 to 0.5)] (Table 4), both validated through sensitivity analysis (Additional File 1: Supplementary Table S8). At T2, when PV individuals had abstained from animal products

for three to four weeks, we report differences in six out of 16 biomarkers, all validated through sensitivity analysis. Specifically, for the PV group we report lower levels of total cholesterol [-0.3 mmol/L (-0.5, -0.2))], LDL cholesterol [-0.3 mmol/L (-0.5, -0.2)], urea [-4.9 mg/dl (-6.4, -3.3)], creatinine [-0.05 mg/dl (-0.08, -0.02)] and γ-GT [-0.1 (-0.2 to -0.003)]. Furthermore, the difference in ALP levels between dietary groups is exacerbated at T2 [5.9 U/L (2.7 to 9.1)]. Additionally, through sensitivity analysis only, we detected a borderline significant difference in glucose levels at T2, with PV individuals displaying slightly lower levels than the NV group (Additional File 1: Supplementary Table S8).

CBC traits

At T1, we report differences for five out of 23 CBC traits between dietary groups, four of which were also validated through sensitivity analysis (Additional File 1: Supplementary Table S9). Specifically, at T1 PV individuals have lower levels of total WBC ([-0.4 K/μL (-0.7 to -0.09)], eosinophils [-0.04 $x10^3$/μL (-0.08 to -0.01)], eosinophil % [-0.5% (-1.0 to -0.1)], and neutrophils [-0.3 $x10^3$/μL (-0.5 to -0.05)] (Table 5). Although not validated through sensitivity analysis (betas and CIs reported in Table 5), we also report lower monocyte levels for the PV group. At T2, two out of 23 CBC traits remain different between dietary groups, with lower levels of total WBC [-0.4 K/μL (-0.8 to -0.1)] and of neutrophils [-0.3 $x10^3$/μL (-0.6 to -0.1)] persisting in PV individuals. These findings were also validated through sensitivity analysis (Additional File 1: Supplementary Table S9).

Anthropometric traits and blood pressure

At T1, PV individuals have a higher BMI compared to the NV group [0.2kg/m^2 (0.08 to 0.4)], but this difference does not hold at T2. No further differences at T1 or T2 are reported for weight and blood pressure measurements between dietary groups (Additional File 1: Supplementary Table S10).

Table 4. Differences in blood biomarkers between dietary groups for each timepoint.

		T1					T2			
Measured traits	**Units**	**T1 Estimate**	***P*-value**	**Lower CI**	**Upper CI**		**T2 Estimate**	***P*-value**	**Lower CI**	**Upper CI**
Blood Biomarkers										
Total cholesterol	mmol/L	0.04	0.6	-0.1	0.2		**-0.3**	**0.0001*** **	**-0.5**	**-0.2**
LDL	mmol/L	-0.001	1.0	-0.2	0.1		**-0.3**	**<0.0001*** **	**-0.5**	**-0.2**
HDL	mmol/L	0.05	0.2	-0.02	0.1		-8.8e-3	0.8	-0.08	0.06
Triglycerides	mmol/L	-1.3e-4	0.9	-2.3e-4	2.1e-3		4.1e-4	0.7	-1.8e-3	2.6e-3
Glucose	mmol/L	-2.1e-4	0.4	-7.8e-4	2.6e-4		0.001	0.07	-0.0001	0.002
Insulin	mU/L	0.008	0.9	-0.1	0.1		0.04	0.5	-0.06	0.1
HbA1c	%	-0.02	0.7	-0.1	0.07		0.05	0.3	-0.04	0.1
Urea	mg/dL	0.7	0.4	-1.0	2.4		**-4.9**	**<0.0001*** **	**-6.4**	**-3.3**
Uric acid	mg/dL	0.1	0.2	-0.06	0.3		-0.1	0.2	-0.3	0.07
Creatinine	mg/dL	-0.01	0.3	-0.05	0.01		**-0.05**	**0.0009** **	**-0.08**	**-0.02**
AST	U/L	0.005	0.9	-0.05	0.06		-0.03	0.3	-0.08	0.02
ALT	U/L	-0.01	0.8	-0.1	0.07		-0.07	0.1	-0.2	0.02
γ-GT	U/L	-0.06	0.3	-0.2	0.05		**-0.1**	**0.05***	**-0.2**	**-0.003**
ALP	U/L	**3.6**	**0.04***	**0.2**	**6.9**		**5.9**	**0.0004** **	**2.7**	**9.1**
TSH	mIU/L	**0.3**	**0.03***	**0.03**	**0.5**		-0.2	0.1	-0.4	0.05
CRP	mg/L	0.2	0.8	-1.1	1.6		-0.6	0.4	-1.9	0.8
HOMA										
HOMA-B	--	-3.4	0.7	-18.9	12.2		12.4	0.2	-5.0	29.8
HOMA-IR	--	-0.5	0.2	-1.2	0.2		-0.01	1.0	-0.7	0.6
P-value: *** ≤ 0.05, ** ≤ 0.001, *** ≤ 0.0001**										

Comparisons are reported with reference to the PV group. Positive effect estimates indicate higher levels of blood biomarkers in the PV compared to the NV group, negative effect estimates indicate lower levels.

LDL = Low-Density Lipoprotein, HDL = High-Density Lipoprotein, HbA1c = Hemoglobin A1c, AST = Aspartate Aminotransferase, ALT = Alanine Aminotransferase, γ-GT = Glutamyltransferase, ALP = Alkaline Phosphatase, TSH = Thyroid-Stimulating Hormone, CRP = C-Reactive Protein, HOMA = Homeostasis Model Assessment, HOMA-B =HOMA-Beta-Cell Function, HOMA-IR = HOMA-Insulin Resistance

Table 5. Differences in CBC traits between dietary groups for each timepoint.

		T1					T2			
Measured traits	**Units**	**T1 Estimate**	***P*-value**	**Lower CI**	**Upper CI**		**T2 Estimate**	***P*-value**	**Lower CI**	**Upper CI**
WBC	K/µL	**-0.4**	**0.01***	**-0.7**	**-0.09**		**-0.4**	**0.006***	**-0.8**	**-0.1**
Lymphocytes	x10³/µl	-0.04	0.4	-0.2	0.07		-0.06	0.3	-0.2	0.05
Lymphocyte %	%	1.1	0.1	-0.3	2.5		1.0	0.2	-0.4	2.4
Eosinophils	x10³/µl	**-0.04**	**0.006***	**-0.08**	**-0.01**		-0.02	0.1	-0.05	0.007
Eosonophil %	%	**-0.5**	**0.01***	**-1.0**	**-0.1**		-0.3	0.2	-0.7	0.2
Monocytes	x10³/µl	**-0.03**	**0.03***	**-0.05**	**-0.002**		-0.02	0.1	-0.05	0.004
Monocyte %	%	-0.08	0.6	-0.4	0.3		0.1	0.5	-0.2	0.5
Basophils	x10³/µl	-9.7e-4	0.6	-0.004	0.003		-0.0006	0.8	-0.004	0.003
Basophil %	%	-0.02	0.4	-0.05	0.02		0.006	0.8	-0.03	0.04
Neutrophils	x10³/µl	**-0.3**	**0.02***	**-0.5**	**-0.05**		**-0.3**	**0.006***	**-0.6**	**-0.1**
Neutrophil %	%	-0.5	0.5	-2.00	1.0		-0.9	0.3	-2.4	0.7
RBC	M/mL	-0.02	0.6	-0.1	0.07		-0.08	0.09	-0.2	0.01
Hemoglobin	g/dL	0.05	0.7	-0.2	0.3		-0.1	0.3	-0.3	0.1
Hematocrit	%	0.1	0.7	-0.4	0.7		-0.3	0.3	-0.8	0.3
MCH	pg	0.2	0.6	-0.4	0.7		0.2	0.5	-0.3	0.7
MCHC	g/dL	0.02	0.8	-0.2	0.2		-0.05	0.6	-0.2	0.1
MCV	fl	0.5	0.5	-1.0	2.0		0.8	0.3	-0.7	2.2
RDW CV	%	-0.2	0.1	-0.4	0.04		-0.1	0.2	-0.4	0.08
RDW SD	fl	-0.2	0.5	-0.8	0.4		0.04	0.9	-0.6	0.7
Platelets	K/µL	8.4	0.09	-1.3	18.1		1.3	0.8	-8.4	11.0
PDW	%	0.3	0.4	-0.4	1.0		0.3	0.4	-0.3	0.9
MPV	µm	0.2	0.4	-0.3	0.7		0.2	0.4	-0.2	0.7
P-LCR	%	0.3	0.8	-1.7	2.3		0.7	0.5	-1.2	2.5

Comparisons are reported with reference to the PV group. Positive effect estimates indicate higher levels of CBC traits for the PV compared to the NV group, negative effect estimates indicate lower levels.

WBC = White Blood Cells, RBC = Red Blood Cells, MCH = Mean Corpuscular Hemoglobin, MCHC = Mean Corpuscular Hemoglobin Concentration, RDW CV = Red Cell Distribution Width Coefficient Of Variation, Red Cell Distribution Width Standard Deviation = RDW SD, PDW = Platelet Distribution Width, MPV = Mean Platelet Volume, P-LCR = Platelet-Large Cell Ratio

DISCUSSION

Principal findings

Abstinence from animal products has prominent, beneficial and most likely rapid effects on blood lipids, thus improving cardiovascular health. It also reduces low-grade inflammation as measured through CRP levels. Furthermore, PV individuals have consistently lower levels of total white blood cells and of neutrophils compared to the NV group. However periodic veganism also has long-term detrimental effects on bone health (Fig. 2), which is substantially worse in PV individuals.

Fig. 2



Summary of key findings: Beneficial and detrimental effects of periodic veganism on health. Three to four weeks on a vegan diet results in a decrease in blood lipids and in low grade inflammation, rendering this type of dietary intervention a powerful means of prevention for a

range of chronic diseases. However, periodic veganism can also compromise bone health of practising individuals in the absence of supplementation.

Figure created with BioRender.com

Comparison with previous studies

Blood lipids

Following three to four weeks on a vegan diet, PV individuals display a prominent reduction by 0.3 mmol/L, of both total and LDL cholesterol. Despite the relatively short duration of the vegan diet, the reduction reported here is larger or comparable to changes reported in meta-analyses of RCTs, where the vegan intervention lasted for at least 12 weeks [5, 6, 10, 11]. In individuals at high risk of CVD, Rees et al report reductions of 0.24 mmol/L and 0.22 mmol/L for total and LDL cholesterol respectively [12]. In healthy individuals, Selinger et al. document a decrease of 0.48 mmol/L in LDL cholesterol, and in individuals with overweight, diabetes or at high risk for CVD, reductions in levels of total and LDL cholesterol ranging from 0.07 to 0.24 mmol/L are reported [6, 11]. Notably, when PV individuals were on an omnivorous diet (T1), the two dietary groups shared a striking resemblance in their blood lipid profile, with almost half of PV and over a third of NV individuals being above highest normal levels for total and LDL cholesterol levels, putting them at high risk for cardiovascular disease (Fig. 1 and Additional File 1: Supplementary Fig. S3). Following the switch to a vegan diet, 18.3% and 15.6% of high-risk PV individuals shift into the normal range for total and LDL cholesterol respectively, suggesting improved cardiovascular health [20]. No such shift was observed for the NV group. To the extent that blood lipids are influenced by diet, this finding suggests a beneficial effect of a vegan diet on cardiovascular disease risk, but also highlights that the omnivorous type of diet followed by both PV and NV groups is on average unhealthy. To put our finding in context, statin use lowers LDL cholesterol levels by an average of 1.8 mmol/L, reducing risk of ischemic heart disease (IHD) events by 60% and of stroke by 17% [21]. Although the effects reported in

the present study are of lower magnitude, the reduction in blood lipids remains marked and suggests that this type of dietary intervention can be used in combination with medication to amplify therapeutic effects or to modulate optimal dosing and to reduce adverse reactions.

Immune system functions

Following DR, a prominent reduction by 1.3 mg/L was recorded for circulating levels of CRP in PV individuals. This corresponds to a 28% drop within normal range values, suggesting a tempering effect of this diet on levels of low-grade inflammation. Some evidence in the same direction is provided by meta-analysis of cross-sectional studies showing that permanent vegans have lower CRP levels compared to omnivorous individuals [22], although in our study, comparison of the two dietary groups at both timepoints did not reveal significant differences in CRP levels. We did however record consistently lower counts of total WBC and of neutrophils in PV compared to NV individuals, at both timepoints, suggesting longer-term effects of periodic veganism on the immune system. We also detected lower eosinophil counts and eosinophil % at T1 for PV individuals.

Importantly, seasonal effects on the immune system are captured by the FastBio study. From autumn (T1) to spring (T2) both dietary groups undergo reductions in total WBCs, neutrophils and neutrophil % and increases in lymphocyte % and monocyte %, in line with findings from the UKBB [18] (with the exception of monocyte %). Furthermore, from T1 to T2, in PV individuals only, we also documented a small decrease in platelets (with a trend towards significance in the sensitivity analysis). In addition to their role in hemostasis and thrombosis, platelets are immune system cells, that can initiate or modulate protective or adverse immune functions [23, 24]. Reductions in platelet levels, as well as in total WBC, neutrophils, and monocytes, have also been documented through a small interventional study involving a four-week vegan diet [18]. Lower platelet and WBC counts have also been reported in permanent vegans compared to non-vegans [25]. Overall, elucidating this type modulatory effect of DR on

the immune system remains a largely untapped resource of enormous potential to enhance therapeutic interventions for prevention and treatment of disease.

Bone health

We have also revealed long-term effects of periodic veganism on ALP, with PV individuals displaying higher levels compared to the NV group, both at T1 (by 3.6 U/L) and at T2 (by 5.9 U/L). This likely reflects long-term, poorer bone health in the PV group, in the absence of supplementation, with an amplification of detrimental effects during the period of veganism. Indeed, large cross-sectional cohort studies have also linked vegan diets to higher risk of bone fractures in the absence of supplementation [8, 9, 26].

Glucose metabolism

Vegan diets have also been linked to weight loss and improved glucose metabolism in individuals with overweight or diabetes [6, 11, 27-29]. In FastBio, both dietary groups are on average overweight, with PV individuals having a significantly higher BMI at both timepoints (Additional file 1: Supplementary Table S2). However, although NV individuals gained approximately one kg on average from autumn (T1) to spring (T2), likely reflecting seasonal weight gain over the winter months [30], PV individuals maintained their initial weight. No changes in levels of glucose were detected across timepoints, but at T2, PV individuals had slightly lower glucose levels than the NV group. Most studies addressing the effects of a vegan diet on glucose metabolism however, typically involve interventions lasting at least 12 weeks and also report effects on HBA1c [11] which take two to three months to become apparent [17]. In the present study, we report a very small reduction in HBA1c (-0.03%) for PV individuals, but this was not validated through sensitivity analysis. For this group, we also report a 13.3 unit increase in HOMA-B. Although an indirect measure of β-cell function [31], this increase may

suggest possible improvement in function of pancreatic β-cells following even a relatively short course of a vegan diet.

Renal, liver and thyroid function

Through the FastBio study we have also documented effects on markers of renal, liver, and thyroid function building on knowledge from cross-sectional studies [10]. At T1, both dietary groups share a very similar profile, but following DR, PV individuals display a better profile compared to the NV group at T2. This stems from reductions observed for the PV group only in levels of urea and creatinine (-5.8 mg/dL and -0.06 mg/dL respectively), the latter reflecting lower intake of animal protein. Additionally, we observed a decrease in levels of ALT (-0.09 U/L) suggesting lower levels of fat deposition in the liver. At T2, γ-GT is reduced for both PV (-0.1 U/L) and NV (-0.009 U/L) groups, reflecting lower levels of alcohol consumption. Although this was expected for the PV group, lower γ-GT levels in the NV group may be a consequence of awareness bias following participation in the study at T1, and subsequent curbing of alcohol consumption prior to T2.

Given that animal products are rich in iodine, vegan individuals may be at risk for low iodine intake [32], resulting in reduced production of thyroxine (T4) and triiodothyronine (T3) and driving increased secretion of thyroid-stimulating hormone (TSH) secretion. At T1, PV individuals display slightly higher levels of TSH (by 0.03 mIU/L) compared to the NV group. However, TSH levels do not change across timepoints for the PV group, but increase for the NV group (by 0.1 mIU/L). No clear effects are reported and further work is necessary to elucidate effects of vegan diets on thyroid function.

Blood pressure

To date no clear effects of a vegan diet on blood pressure have been detected in healthy and in overweight individuals, or in persons with underlying disease or at CVD risk [6, 11, 12]. In the present study we detected very small drops (~ -2.2 mmHg) in both SBP and DBP for both dietary

groups across timepoints (with SBP changes in PV trending towards significance), likely reflecting seasonal effects [33]. No differences were detected between dietary groups.

Strengths and limitations

The FastBio study comprises one of the most comprehensive studies addressing the effects of a vegan diet on health, reporting on 16 biomarker and 23 CBC traits as well as on anthropometric and blood pressure traits. Although the duration of DR in FastBio is relatively short, we report larger or comparable effects on a number of measured traits (e.g. total and LDL cholesterol) compared to others [6, 11, 12]. This may stem partially from the very high consistency in the specific type of DR practised by PV individuals, and the fact that they have adhered to this regimen for at least ten years. The FastBio study also enables us to disentangle effects driven by seasonality and given the sampling strategy applied, to minimise circadian effects on traits such as WBCs and CRP that are known to display significant daily variation [15]. Although PV and NV groups display differences in age, BMI and smoking behaviour, given our study design, the changes across timepoints are captured through the paired data structure, therefore each individual acts as his/her own control. Furthermore, adjustments for known confounders including age, sex and BMI were applied on each model.

A limitation of the FastBio study is that traits were measured at two distinct timepoints (approximately five months apart), but not immediately prior to initiation of DR, meaning that we do not have baseline measurements. Our hypothesis however is that prior to initiation of abstinence, PV individuals would have had a similar biological profile to that at T1, given that they had undergone a period of omnivory that was similar in length to the period of omnivory prior to T1. A second limitation of our study is that we did not measure caloric intake for either dietary group and also cannot ascertain direct effects on weight given lack of baseline measurements. Finally, although we have adjusted for confounding factors, some residual effects may persist in reported results.

CONCLUSIONS

The FastBio study highlights beneficial effects of periodic veganism on blood lipids, on renal and liver health, and a tempering effect on low-grade inflammation and modulation of immune system function, suggesting that this type of periodic modification of dietary intake can drive better metabolic health and can moderate risk for a range of diseases. However, we also report likely detrimental effects on bone health in the absence of appropriate supplementation, and thus highlight the need for further work in this field to map beneficial and damaging effects of different types of DR on health. Ultimately, harnessing dietary interventions as a means of chronic disease prevention and therapy, is a promising approach that can be applied synergistically to pharmacological treatment. Our results suggest that periodic veganism may inform on future public health dietary guidelines that can be utilized by the medical community as a personalized chronic disease prevention strategy. This is all the more feasible with dietary options that are relatively easy to adhere to, such as periodic veganism.

Abbreviations

DR = Dietary Restriction, PV = Periodic Vegans, NV = Non-vegans, T1 = Timepoint 1, T2 = Timepoint 2, BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure, LDL = Low-Density Lipoprotein, HDL = High-Density Lipoprotein, Hba1c = Hemoglobin A1c, AST = Aspartate Aminotransferase, ALT = Alanine Aminotransferase, Γ-GT = Glutamyltransferase, ALP = Alkaline Phosphatase, TSH = Thyroid-Stimulating Hormone, CRP = C-Reactive Protein, HOMA = Homeostasis Model Assessment, HOMA-B =HOMA-Beta-Cell Function, HOMA-IR = HOMA-Insulin Resistance, WBC = White Blood Cells, RBC = Red Blood Cells, MCH = Mean Corpuscular Hemoglobin, MCHC = Mean Corpuscular Hemoglobin Concentration, RDW CV = Red Cell Distribution Width Coefficient of Variation, Red Cell Distribution Width Standard Deviation = RDW SD, PDW = Platelet Distribution Width, MPV = Mean Platelet Volume, P-LCR = Platelet-Large Cell Ratio

Acknowledgements

The authors would like to thank the FastBio study participants and the Interbalkan Hospital staff. We would also like to thank Dr Dimitrios Rouskas and Dr Loukas Kipouros for their invaluable help with recruitment of participants.

Author contributions

Material preparation, participant recruitment, collection of biological material and data collection were performed by ASD, KR, PR, SG, AD and MA. IK and ND provided statistical consultation. Statistical analyses were performed by EML, PB and ASD. ASD, EML, KR, PR, IK and ND interpreted the results. The first draft of the manuscript was written by EML and ASD and all authors commented on the manuscript. All authors read and approved the final manuscript.

Funding

The FastBio study was supported through a European Research Council Grant to Antigone Dimas (FastBio – 716998).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

DECLARATIONS

Ethics approval and consent to participate

Ethical approval was granted from the ethics committee of BSRC Alexander Fleming which approved the study protocols. The study was performed in line with the principles of the Declaration of Helsinki, and all participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

REFERENCES

1. Katewa, S.D. and P. Kapahi, *Dietary restriction and aging, 2009.* Aging Cell, 2010. **9**(2): p. 105-12.
2. Zhang, S., Y. Yan, G. Meng, Q. Zhang, L. Liu, H. Wu, et al., *Protein foods from animal sources and risk of nonalcoholic fatty liver disease in representative cohorts from North and South China.* J Intern Med, 2023. **293**(3): p. 340-353.
3. Wilson, K.A., M. Chamoli, T.A. Hilsabeck, M. Pandey, S. Bansal, G. Chawla, et al., *Evaluating the beneficial effects of dietary restrictions: A framework for precision nutrigeroscience.* Cell Metab, 2021. **33**(11): p. 2142-2173.
4. Green, C.L., D.W. Lamming, and L. Fontana, *Molecular mechanisms of dietary restriction promoting health and longevity.* Nat Rev Mol Cell Biol, 2022. **23**(1): p. 56-73.
5. Key, T.J., K. Papier, and T.Y.N. Tong, *Plant-based diets and long-term health: findings from the EPIC-Oxford study.* Proc Nutr Soc, 2022. **81**(2): p. 190-198.
6. Selinger, E., M. Neuenschwander, A. Koller, J. Gojda, T. Kühn, L. Schwingshackl, et al., *Evidence of a vegan diet for health benefits and risks – an umbrella review of meta-analyses of observational and clinical studies.* Critical Reviews in Food Science and Nutrition, 2022: p. 1-11.
7. Dinu, M., R. Abbate, G.F. Gensini, A. Casini, and F. Sofi, *Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies.* Crit Rev Food Sci Nutr, 2017. **57**(17): p. 3640-3649.
8. Tong, T.Y.N., P.N. Appleby, M.E.G. Armstrong, G.K. Fensom, A. Knuppel, K. Papier, et al., *Vegetarian and vegan diets and risks of total and site-specific fractures: results from the prospective EPIC-Oxford study.* BMC Med, 2020. **18**(1): p. 353.
9. Webster, J., D.C. Greenwood, and J.E. Cade, *Risk of hip fracture in meat-eaters, pescatarians, and vegetarians: results from the UK Women's Cohort Study.* BMC Medicine, 2022. **20**(1): p. 275.
10. Tong, T.Y.N., A. Perez-Cornago, K.E. Bradbury, and T.J. Key, *Biomarker Concentrations in White and British Indian Vegetarians and Nonvegetarians in the UK Biobank.* J Nutr, 2021. **151**(10): p. 3168-3179.
11. Termannsen, A.D., K.K.B. Clemmensen, J.M. Thomsen, O. Norgaard, L.J. Diaz, S.S. Torekov, et al., *Effects of vegan diets on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials.* Obes Rev, 2022. **23**(9): p. e13462.
12. Rees, K., L. Al-Khudairy, A. Takeda, and S. Stranges, *Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases.* Cochrane Database Syst Rev, 2021. **2**(2): p. Cd013501.
13. Yokoyama, Y., S.M. Levin, and N.D. Barnard, *Association between plant-based diets and plasma lipids: a systematic review and meta-analysis.* Nutr Rev, 2017. **75**(9): p. 683-698.
14. Koelman, L., C. Egea Rodrigues, and K. Aleksandrova, *Effects of Dietary Patterns on Biomarkers of Inflammation and Immune Responses: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.* Adv Nutr, 2022. **13**(1): p. 101-115.
15. Wyse, C., G. O'Malley, A.N. Coogan, S. McConkey, and D.J. Smith, *Seasonal and daytime variation in multiple immune parameters in humans: Evidence from 329,261 participants of the UK Biobank cohort.* iScience, 2021. **24**(4): p. 102255.
16. Primatesta, P., E. Falaschetti, S. Gupta, M.G. Marmot, and N.R. Poulter, *Association between smoking and blood pressure: evidence from the health survey for England.* Hypertension, 2001. **37**(2): p. 187-93.
17. Hanas, R., G. John, and I.H.c.C. Committee, *2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement.* Diabetes Care, 2010. **33**(8): p. 1903-4.
18. Lederer, A.K., A. Maul-Pavicic, L. Hannibal, M. Hettich, C. Steinborn, C. Gründemann, et al., *Vegan diet reduces neutrophils, monocytes and platelets related to branched-chain amino acids - A randomized, controlled trial.* Clin Nutr, 2020. **39**(11): p. 3241-3250.

19. Kjeldsen-Kragh, J., M. Haugen, C.F. Borchgrevink, E. Laerum, M. Eek, P. Mowinkel, et al., *Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis.* Lancet, 1991. **338**(8772): p. 899-902.
20. Mach, F., C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, et al., *2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.* Eur Heart J, 2020. **41**(1): p. 111-188.
21. Law, M.R., N.J. Wald, and A.R. Rudnicka, *Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.* BMJ, 2003. **326**(7404): p. 1423.
22. Menzel, J., A. Jabakhanji, R. Biemann, K. Mai, K. Abraham, and C. Weikert, *Systematic review and meta-analysis of the associations of vegan and vegetarian diets with inflammatory biomarkers.* Sci Rep, 2020. **10**(1): p. 21736.
23. Morrell, C.N., A.A. Aggrey, L.M. Chapman, and K.L. Modjeski, *Emerging roles for platelets as immune and inflammatory cells.* Blood, 2014. **123**(18): p. 2759-67.
24. Chen, Y., H. Zhong, Y. Zhao, X. Luo, and W. Gao, *Role of platelet biomarkers in inflammatory response.* Biomark Res, 2020. **8**: p. 28.
25. Haddad, E.H., L.S. Berk, J.D. Kettering, R.W. Hubbard, and W.R. Peters, *Dietary intake and biochemical, hematologic, and immune status of vegans compared with nonvegetarians.* Am J Clin Nutr, 1999. **70**(3 Suppl): p. 586S-593S.
26. Ogilvie, A.R., B.D. McGuire, L. Meng, and S.A. Shapses, *Fracture Risk in Vegetarians and Vegans: the Role of Diet and Metabolic Factors.* Curr Osteoporos Rep, 2022. **20**(6): p. 442-452.
27. Mishra, S., J. Xu, U. Agarwal, J. Gonzales, S. Levin, and N.D. Barnard, *A multicenter randomized controlled trial of a plant-based nutrition program to reduce body weight and cardiovascular risk in the corporate setting: the GEICO study.* Eur J Clin Nutr, 2013. **67**(7): p. 718-24.
28. Tong, T.Y.N., P.N. Appleby, M.E.G. Armstrong, G.K. Fensom, A. Knuppel, K. Papier, et al., *Vegetarian and vegan diets and risks of total and site-specific fractures: results from the prospective EPIC-Oxford study.* BMC Medicine, 2020. **18**(1): p. 353.
29. Spencer, E.A., P.N. Appleby, G.K. Davey, and T.J. Key, *Diet and body mass index in 38 000 EPIC-Oxford meat-eaters, fish-eaters, vegetarians and vegans.* International Journal of Obesity, 2003. **27**(6): p. 728-734.
30. Turicchi, J., R. O'Driscoll, G. Horgan, C. Duarte, A.L. Palmeira, S.C. Larsen, et al., *Weekly, seasonal and holiday body weight fluctuation patterns among individuals engaged in a European multi-centre behavioural weight loss maintenance intervention.* PLoS One, 2020. **15**(4): p. e0232152.
31. Chow, E.Y.K. and J.C.N. Chan, *Insulin resistance versus β-cell dysfunction in type 2 diabetes: where public and personalised health meet.* Lancet Diabetes Endocrinol, 2020. **8**(2): p. 92-93.
32. Leung, A.M., A. Lamar, X. He, L.E. Braverman, and E.N. Pearce, *Iodine status and thyroid function of Boston-area vegetarians and vegans.* J Clin Endocrinol Metab, 2011. **96**(8): p. E1303-7.
33. Lewington, S., L. Li, P. Sherliker, Y. Guo, I. Millwood, Z. Bian, et al., *Seasonal variation in blood pressure and its relationship with outdoor temperature in 10 diverse regions of China: the China Kadoorie Biobank.* J Hypertens, 2012. **30**(7): p. 1383-91.